Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Ladarixin Bioavailability
NCT04854642Phase 1Completed
- Sponsor
- Dompé
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ladarixin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Dompé. Primary endpoints: Maximum Plasma Concentration of Ladarixin (DF 2156Y) at Day 4 and Area Under the Curve from time 0 to last measurable concentration for Ladarixin (DF 2156Y) at Day 4. Started Oct 2020; status: completed.
02
Drugs
ladarixin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04854642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854642.